Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
CAM encourages corneal healing in patients with ocular surface disease.
Long-term sustained-release therapy pays off in management of chronic, vision-threatening disease.
Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).
Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.
This article is produced by iCare Finland for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
Examining an intraocular implant that can sharpen vision for patients as disease progresses.
Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF agents like aflibercept 8 mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for extended treatment intervals of 9 to 10 weeks compared to monthly dosing with earlier agents, while improving anatomic outcomes and visual acuity.
Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.
Tunde Peto, MD, PhD, discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.
A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.
The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.
Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.
The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Micoaneurysm turnover in the early stages of diabetic retinopathy predicts how much the disease will progress, according to researchers.
OCT has many benefits, yet falls short of reliably diagnosing and managing retinopathies and glaucoma. ERG remains the stalwart method for this application and this article highlights how technological advancements have enabled its introduction to the clinic.
ICYMI: Dr. Clark breaks down the results of the PANORAMA Study
A dark adaptometer (AdaptDx; MacuLogix Inc) can aid in the diagnosis of early-stage, or subclinical, age-related macular degeneration before visual loss occurs and even before structural changes are observed, and adds to the information obtained from retina cameras and OCT imaging.
FDA decision changes scope of healthcare delivery; increases patient access to early detection of DR
Treating diabetic macular edema (DME) has evolved from the ETDRS-style focal/grid laser being the standard of care since 1985 to the modern era of pharmacotherapy-with anti-vascular endothelial growth factor (VEGF) injections now taking center stage as primary treatment for most patients.
Earlier this month, a jury convicted West Palm Beach retina surgeon Solomon Melgen, MD, on 67 counts of Medicare fraud. This high-profile case hit very close to home, as myself and another retina specialist from my own community were on opposing sides of the case.
The importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.
Idiopathic macular telangiectasia (MacTel) is bilateral condition characterised by ectatic capillaries of the macula and atrophy of the neurosensory retina. Familiarity with the distinctive intraretinal cavitation on SD-OCT in type 2, the most common type, is key for correct diagnosis.